Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 60

1.

Local immunomodulation with Fas ligand-engineered biomaterials achieves allogeneic islet graft acceptance.

Headen DM, Woodward KB, Coronel MM, Shrestha P, Weaver JD, Zhao H, Tan M, Hunckler MD, Bowen WS, Johnson CT, Shea L, Yolcu ES, García AJ, Shirwan H.

Nat Mater. 2018 Jun 4. doi: 10.1038/s41563-018-0099-0. [Epub ahead of print]

PMID:
29867165
2.

Fas/Fas-Ligand Interaction As a Mechanism of Immune Homeostasis and β-Cell Cytotoxicity: Enforcement Rather Than Neutralization for Treatment of Type 1 Diabetes.

Yolcu ES, Shirwan H, Askenasy N.

Front Immunol. 2017 Mar 27;8:342. doi: 10.3389/fimmu.2017.00342. eCollection 2017. No abstract available.

3.

Mechanisms of Tolerance Induction by Hematopoietic Chimerism: The Immune Perspective.

Yolcu ES, Shirwan H, Askenasy N.

Stem Cells Transl Med. 2017 Mar;6(3):700-712. doi: 10.1002/sctm.16-0358. Epub 2017 Jan 3.

4.

4-1BB Signaling in Conventional T Cells Drives IL-2 Production That Overcomes CD4+CD25+FoxP3+ T Regulatory Cell Suppression.

Barsoumian HB, Yolcu ES, Shirwan H.

PLoS One. 2016 Apr 6;11(4):e0153088. doi: 10.1371/journal.pone.0153088. eCollection 2016.

5.

SA-4-1BBL/MPL as a novel immune adjuvant platform to combat cancer.

Srivastava AK, Yolcu ES, Dinc G, Sharma RK, Shirwan H.

Oncoimmunology. 2015 Jul 1;5(1):e1064580. eCollection 2016.

6.

Novel technologies to engineer graft for tolerance induction.

Woodward KB, Wang F, Zhao H, Yolcu ES, Shirwan H.

Curr Opin Organ Transplant. 2016 Feb;21(1):74-80. doi: 10.1097/MOT.0000000000000270. Review.

7.

Characterization of Human CD8(+)TCR(-) Facilitating Cells In Vitro and In Vivo in a NOD/SCID/IL2rγ(null) Mouse Model.

Huang Y, Elliott MJ, Yolcu ES, Miller TO, Ratajczak J, Bozulic LD, Wen Y, Xu H, Ratajczak MZ, Ildstad ST.

Am J Transplant. 2016 Feb;16(2):440-53. doi: 10.1111/ajt.13511. Epub 2015 Nov 9.

8.

Immune reconstitution/immunocompetence in recipients of kidney plus hematopoietic stem/facilitating cell transplants.

Leventhal JR, Elliott MJ, Yolcu ES, Bozulic LD, Tollerud DJ, Mathew JM, Konieczna I, Ison MG, Galvin J, Mehta J, Badder MD, Abecassis MM, Miller J, Gallon L, Ildstad ST.

Transplantation. 2015 Feb;99(2):288-98. doi: 10.1097/TP.0000000000000605.

PMID:
25594553
9.

Facilitating cells in tolerance induction for kidney transplantation.

Yolcu ES, Leventhal JR, Ildstad ST.

Curr Opin Organ Transplant. 2015 Feb;20(1):57-63. doi: 10.1097/MOT.0000000000000156. Review.

PMID:
25522139
10.

SA-4-1BBL and monophosphoryl lipid A constitute an efficacious combination adjuvant for cancer vaccines.

Srivastava AK, Dinc G, Sharma RK, Yolcu ES, Zhao H, Shirwan H.

Cancer Res. 2014 Nov 15;74(22):6441-51. doi: 10.1158/0008-5472.CAN-14-1768-A. Epub 2014 Sep 24.

11.

Improving the Th1 cellular efficacy of the lead Yersinia pestis rF1-V subunit vaccine using SA-4-1BBL as a novel adjuvant.

Dinc G, Pennington JM, Yolcu ES, Lawrenz MB, Shirwan H.

Vaccine. 2014 Sep 3;32(39):5035-40. doi: 10.1016/j.vaccine.2014.07.015. Epub 2014 Jul 18.

PMID:
25045812
12.

The direct display of costimulatory proteins on tumor cells as a means of vaccination for cancer immunotherapy.

Shirwan H, Yolcu ES, Sharma RK, Zaho H, Grimany-Nuno O.

Methods Mol Biol. 2014;1139:269-85. doi: 10.1007/978-1-4939-0345-0_23.

PMID:
24619687
13.

SA-4-1BBL as a novel adjuvant for the development of therapeutic cancer vaccines.

Sharma RK, Yolcu ES, Shirwan H.

Expert Rev Vaccines. 2014 Mar;13(3):387-98. doi: 10.1586/14760584.2014.880340. Review.

14.

Fragmented sleep accelerates tumor growth and progression through recruitment of tumor-associated macrophages and TLR4 signaling.

Hakim F, Wang Y, Zhang SX, Zheng J, Yolcu ES, Carreras A, Khalyfa A, Shirwan H, Almendros I, Gozal D.

Cancer Res. 2014 Mar 1;74(5):1329-37. doi: 10.1158/0008-5472.CAN-13-3014. Epub 2014 Jan 21.

15.

CD4+ T cells play a critical role in the generation of primary and memory antitumor immune responses elicited by SA-4-1BBL and TAA-based vaccines in mouse tumor models.

Sharma RK, Yolcu ES, Srivastava AK, Shirwan H.

PLoS One. 2013 Sep 16;8(9):e73145. doi: 10.1371/journal.pone.0073145. eCollection 2013.

16.

Immunomodulation with SA-FasL protein as an effective means of preventing islet allograft rejection in chemically diabetic NOD mice.

Yolcu ES, Zhao H, Shirwan H.

Transplant Proc. 2013 Jun;45(5):1889-91. doi: 10.1016/j.transproceed.2013.01.041.

17.
18.

Posttransplantation systemic immunomodulation with SA-FasL-engineered donor splenocytes has robust efficacy in preventing cardiac allograft rejection in mice.

Zhao H, Woodward KB, Shirwan H, Grimany-Nuno O, Yolcu ES.

Transplant Proc. 2013 Jun;45(5):1805-7. doi: 10.1016/j.transproceed.2013.01.049.

19.

Immunomodulation with donor regulatory T cells armed with Fas-ligand alleviates graft-versus-host disease.

Yolcu ES, Kaminitz A, Mizrahi K, Ash S, Yaniv I, Stein J, Shirwan H, Askenasy N.

Exp Hematol. 2013 Oct;41(10):903-11. doi: 10.1016/j.exphem.2013.04.016. Epub 2013 Jun 4.

PMID:
23743300
20.

Co-stimulatory tumor necrosis factor ligands as adjuvants for the development of subunit-based anticancer vaccines.

Shirwan H, Sharma RK, Srivastava AK, Yolcu ES.

Oncoimmunology. 2013 Apr 1;2(4):e23440.

21.

Killer Treg cells ameliorate inflammatory insulitis in non-obese diabetic mice through local and systemic immunomodulation.

Kaminitz A, Yolcu ES, Mizrahi K, Shirwan H, Askenasy N.

Int Immunol. 2013 Aug;25(8):485-94. doi: 10.1093/intimm/dxt016. Epub 2013 May 8.

PMID:
23657001
22.

Immunomodulation with regulatory T cells and Fas-ligand ameliorate established inflammatory colitis.

Kaminitz A, Askenasy N, Yolcu ES.

Gut. 2013 Aug;62(8):1228-30. doi: 10.1136/gutjnl-2012-304432. Epub 2013 Feb 22. No abstract available.

PMID:
23436337
23.

Prime-boost vaccination with SA-4-1BBL costimulatory molecule and survivin eradicates lung carcinoma in CD8+ T and NK cell dependent manner.

Srivastava AK, Sharma RK, Yolcu ES, Ulker V, MacLeod K, Dinc G, Shirwan H.

PLoS One. 2012;7(11):e48463. doi: 10.1371/journal.pone.0048463. Epub 2012 Nov 8.

24.

SA-4-1BBL costimulation inhibits conversion of conventional CD4+ T cells into CD4+ FoxP3+ T regulatory cells by production of IFN-γ.

Madireddi S, Schabowsky RH, Srivastava AK, Sharma RK, Yolcu ES, Shirwan H.

PLoS One. 2012;7(8):e42459. doi: 10.1371/journal.pone.0042459. Epub 2012 Aug 1. Erratum in: PLoS One. 2012;7(8): doi/10.1371/annotation/88b557df-1e27-4a60-8b47-214a5cc3c707.

25.

Engineering of bone marrow cells with fas-ligand protein-enhances donor-specific tolerance to solid organs.

Askenasy EM, Shushlav Y, Sun Z, Shirwan H, Yolcu ES, Askenasy N.

Transplant Proc. 2011 Nov;43(9):3545-8. doi: 10.1016/j.transproceed.2011.08.046.

PMID:
22099838
26.

Pancreatic islets engineered with SA-FasL protein establish robust localized tolerance by inducing regulatory T cells in mice.

Yolcu ES, Zhao H, Bandura-Morgan L, Lacelle C, Woodward KB, Askenasy N, Shirwan H.

J Immunol. 2011 Dec 1;187(11):5901-9. doi: 10.4049/jimmunol.1003266. Epub 2011 Nov 7.

27.

Effector and naturally occurring regulatory T cells display no abnormalities in activation induced cell death in NOD mice.

Kaminitz A, Yolcu ES, Askenasy EM, Stein J, Yaniv I, Shirwan H, Askenasy N.

PLoS One. 2011;6(6):e21630. doi: 10.1371/journal.pone.0021630. Epub 2011 Jun 27.

28.

Killer Treg restore immune homeostasis and suppress autoimmune diabetes in prediabetic NOD mice.

Kaminitz A, Yolcu ES, Stein J, Yaniv I, Shirwan H, Askenasy N.

J Autoimmun. 2011 Aug;37(1):39-47. doi: 10.1016/j.jaut.2011.03.003. Epub 2011 Apr 15.

PMID:
21497486
29.

[Allograft tolerance induced by FasL chimeric protein decorated donor splenocytes].

Gu X, Yang J, Zhao H, Yolcu ES, Shirwan H.

Zhonghua Wai Ke Za Zhi. 2010 May 1;48(9):702-5. Chinese.

PMID:
20646556
30.

SA-4-1BBL as the immunomodulatory component of a HPV-16 E7 protein based vaccine shows robust therapeutic efficacy in a mouse cervical cancer model.

Sharma RK, Srivastava AK, Yolcu ES, MacLeod KJ, Schabowsky RH, Madireddi S, Shirwan H.

Vaccine. 2010 Aug 16;28(36):5794-802. doi: 10.1016/j.vaccine.2010.06.073. Epub 2010 Jul 4.

31.

Tumor cells engineered to codisplay on their surface 4-1BBL and LIGHT costimulatory proteins as a novel vaccine approach for cancer immunotherapy.

Sharma RK, Yolcu ES, Elpek KG, Shirwan H.

Cancer Gene Ther. 2010 Oct;17(10):730-41. doi: 10.1038/cgt.2010.29. Epub 2010 Jun 18.

32.

Tumor necrosis factor receptors support murine hematopoietic progenitor function in the early stages of engraftment.

Pearl-Yafe M, Mizrahi K, Stein J, Yolcu ES, Kaplan O, Shirwan H, Yaniv I, Askenasy N.

Stem Cells. 2010 Jul;28(7):1270-80. doi: 10.1002/stem.448.

33.

4-1BB ligand as an effective multifunctional immunomodulator and antigen delivery vehicle for the development of therapeutic cancer vaccines.

Sharma RK, Schabowsky RH, Srivastava AK, Elpek KG, Madireddi S, Zhao H, Zhong Z, Miller RW, Macleod KJ, Yolcu ES, Shirwan H.

Cancer Res. 2010 May 15;70(10):3945-54. doi: 10.1158/0008-5472.CAN-09-4480. Epub 2010 Apr 20.

34.

A novel form of 4-1BBL has better immunomodulatory activity than an agonistic anti-4-1BB Ab without Ab-associated severe toxicity.

Schabowsky RH, Elpek KG, Madireddi S, Sharma RK, Yolcu ES, Bandura-Morgan L, Miller R, MacLeod KJ, Mittler RS, Shirwan H.

Vaccine. 2009 Dec 11;28(2):512-22. doi: 10.1016/j.vaccine.2009.09.127. Epub 2009 Oct 29.

35.

ProtEx technology for the generation of novel therapeutic cancer vaccines.

Schabowsky RH, Sharma RK, Madireddi S, Srivastava A, Yolcu ES, Shirwan H.

Exp Mol Pathol. 2009 Jun;86(3):198-207. doi: 10.1016/j.yexmp.2009.01.010. Epub 2009 Jan 31. Review.

36.

Costimulation as a platform for the development of vaccines: a peptide-based vaccine containing a novel form of 4-1BB ligand eradicates established tumors.

Sharma RK, Elpek KG, Yolcu ES, Schabowsky RH, Zhao H, Bandura-Morgan L, Shirwan H.

Cancer Res. 2009 May 15;69(10):4319-26. doi: 10.1158/0008-5472.CAN-08-3141. Epub 2009 May 12.

37.

Apoptosis as a mechanism of T-regulatory cell homeostasis and suppression.

Yolcu ES, Ash S, Kaminitz A, Sagiv Y, Askenasy N, Yarkoni S.

Immunol Cell Biol. 2008 Nov-Dec;86(8):650-8. doi: 10.1038/icb.2008.62. Epub 2008 Sep 16. Review.

PMID:
18794907
38.

Induction of tolerance to cardiac allografts using donor splenocytes engineered to display on their surface an exogenous fas ligand protein.

Yolcu ES, Gu X, Lacelle C, Zhao H, Bandura-Morgan L, Askenasy N, Shirwan H.

J Immunol. 2008 Jul 15;181(2):931-9.

39.

Targeting CD4+CD25+FoxP3+ regulatory T-cells for the augmentation of cancer immunotherapy.

Schabowsky RH, Madireddi S, Sharma R, Yolcu ES, Shirwan H.

Curr Opin Investig Drugs. 2007 Dec;8(12):1002-8. Review.

PMID:
18058571
40.

Ex vivo expansion of CD4+CD25+FoxP3+ T regulatory cells based on synergy between IL-2 and 4-1BB signaling.

Elpek KG, Yolcu ES, Franke DD, Lacelle C, Schabowsky RH, Shirwan H.

J Immunol. 2007 Dec 1;179(11):7295-304.

41.

Expression of Fas and Fas-ligand in donor hematopoietic stem and progenitor cells is dissociated from the sensitivity to apoptosis.

Pearl-Yafe M, Yolcu ES, Stein J, Kaplan O, Shirwan H, Yaniv I, Askenasy N.

Exp Hematol. 2007 Oct;35(10):1601-12.

PMID:
17889725
42.

Fas transduces dual apoptotic and trophic signals in hematopoietic progenitors.

Pearl-Yafe M, Stein J, Yolcu ES, Farkas DL, Shirwan H, Yaniv I, Askenasy N.

Stem Cells. 2007 Dec;25(12):3194-203. Epub 2007 Sep 13.

43.
44.

Fas ligand enhances hematopoietic cell engraftment through abrogation of alloimmune responses and nonimmunogenic interactions.

Pearl-Yafe M, Yolcu ES, Stein J, Kaplan O, Yaniv I, Shirwan H, Askenasy N.

Stem Cells. 2007 Jun;25(6):1448-55. Epub 2007 Mar 15.

45.

Pancreatic islets under attack: cellular and molecular effectors.

Pearl-Yafe M, Kaminitz A, Yolcu ES, Yaniv I, Stein J, Askenasy N.

Curr Pharm Des. 2007;13(7):749-60. Review.

PMID:
17346189
46.

A novel multimeric form of FasL modulates the ability of diabetogenic T cells to mediate type 1 diabetes in an adoptive transfer model.

Franke DD, Yolcu ES, Alard P, Kosiewicz MM, Shirwan H.

Mol Immunol. 2007 Apr;44(11):2884-92. Epub 2007 Feb 26.

47.

Primary tumor cells resected from cancer patients and decorated with a novel form of CD80 protein serve as effective antigen-presenting cells for the induction of autologous T cell immune responses ex vivo.

Singh NP, Miller RW, Yolcu ES, Kilinc MO, Oechsli M, Huseby R, Taylor DD, Perry MT, Larocca RV, Shirwan H.

Hum Gene Ther. 2006 Mar;17(3):334-46.

PMID:
16544982
48.

Generation of a multimeric form of CD40L with potent immunostimulatory activity using streptavidin as a chaperon.

Kilinc MO, Mukundan L, Yolcu ES, Singh NP, Suttles J, Shirwan H.

Exp Mol Pathol. 2006 Jun;80(3):252-61. Epub 2006 Feb 17.

PMID:
16487512
49.

The dual role of Fas-ligand as an injury effector and defense strategy in diabetes and islet transplantation.

Pearl-Yafe M, Yolcu ES, Yaniv I, Stein J, Shirwan H, Askenasy N.

Bioessays. 2006 Feb;28(2):211-22.

PMID:
16435302
50.

ProtEx: a novel technology to display exogenous proteins on the cell surface for immunomodulation.

Singh NP, Yolcu ES, Askenasy N, Shirwan H.

Ann N Y Acad Sci. 2005 Nov;1056:344-58.

PMID:
16387700

Supplemental Content

Loading ...
Support Center